Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

1.520 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,502
Open 1.520
Bid (Size) 1.500 (4,100)
Ask (Size) 1.540 (600)
Prev. Close 1.520
Today's Range 1.520 - 1.520
52wk Range 1.090 - 6.230
Shares Outstanding 3,504,950
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Via Investor Brand Network
Topics Government
News headline image
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
From BioMedWire
Via GlobeNewswire

Performance

YTD
-48.3%
-48.3%
1 Month
+3.4%
+3.4%
3 Month
-51.1%
-51.1%
6 Month
-19.6%
-19.6%
1 Year
-54.2%
-54.2%

More News

Read More
Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally ↗
Via Stocktwits
Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate
Via Investor Brand Network
Study Uncovers Surprising Connection Between Choline, Obesity and Brain Inflammation
Via Investor Brand Network
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
Via Investor Brand Network
Parent Explains Why it is Wrong to Say Vaccines Cause Autism
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results
Via Investor Brand Network
Surface Sugars on Immune Cells Linked to the Progression of Psoriasis
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Eyes Dermatology Market with SGX302’s Encouraging Early Results
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma
Via Investor Brand Network
Topics Retirement
$37.5M Grant Announced to Boost Management of Infectious Diseases in the US
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results
Via Investor Brand Network
Researchers Develop Nanoparticles That Could Combat Scarring, Inflammation in ARLD
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026
Via Investor Brand Network
How You Can Support Your Loved One Undergoing Cancer Treatment
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL
Via Investor Brand Network

Frequently Asked Questions

Is Soligenix, Inc. - Common Stock publicly traded?
Yes, Soligenix, Inc. - Common Stock is publicly traded.
What exchange does Soligenix, Inc. - Common Stock trade on?
Soligenix, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soligenix, Inc. - Common Stock?
The ticker symbol for Soligenix, Inc. - Common Stock is SNGX on the Nasdaq Stock Market
What is the current price of Soligenix, Inc. - Common Stock?
The current price of Soligenix, Inc. - Common Stock is 1.520
When was Soligenix, Inc. - Common Stock last traded?
The last trade of Soligenix, Inc. - Common Stock was at 12/01/25 04:00 PM ET
What is the market capitalization of Soligenix, Inc. - Common Stock?
The market capitalization of Soligenix, Inc. - Common Stock is 5.33M
How many shares of Soligenix, Inc. - Common Stock are outstanding?
Soligenix, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.